Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + SBRT/Hypo-fractionated RT in Stage I-III NSCLC
NCT05451173Phase 2Not yet recruiting
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC). Planned start Oct 2023; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05451173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451173.